Cardiol Therapeutics (CRDL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

CRDL · Stock Price

USD 1.30+0.15 (+13.04%)

Market Cap: $145.7M

Historical price data

Overview

Cardiol Therapeutics is a focused, clinical-stage biotechnology company dedicated to developing innovative treatments for heart disease. Its core strategy leverages the anti-inflammatory and anti-fibrotic properties of a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation, CardiolRx™, currently in two Phase II trials for inflammatory cardiac conditions. The company aims to address substantial unmet medical needs in cardiology through a targeted, scientifically-driven approach, supported by public market financing.

Cardiovascular

Technology Platform

A drug development platform focused on creating proprietary, pharmaceutical-grade formulations of cannabidiol (CBD) to target inflammation and fibrosis in cardiac tissue.

Opportunities

CardiolRx™ addresses multi-billion dollar unmet needs in recurrent pericarditis and acute myocarditis.

Success in Phase II trials could enable a first-mover position in myocarditis and provide a differentiated oral therapy in pericarditis, leading to high-value partnerships or strategic acquisition.

Risk Factors

High clinical trial failure risk, regulatory hurdles for a CBD-based drug, heavy dependence on a single asset, and future shareholder dilution from necessary capital raises to fund operations and trials.

Competitive Landscape

Faces direct competition from Kiniksa's approved drug in pericarditis and earlier-stage programs. In myocarditis, competes against off-label generics but has a potential first-mover advantage with one of the most advanced targeted clinical programs.

More companies in Canada →